<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001181.v1.p1" parentStudy="phs001181.v1.p1" createDate="2016-08-03" modDate="2017-03-21">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Michael Dean, PhD</td><td>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Funding Source</td><td>HHSN261200800001E</td><td>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Funding Source</td><td>CXZZ20150330171838997</td><td>Shenzhen Science and Technology Program, Shenzhen, China</td></tr>
		<tr><td>Funding Source</td><td>ZDSYS20140509153457495</td><td>Shenzhen Municipal Government, Shenzhen, China</td></tr>
		<tr><td>Funding Source</td><td>JSGG20140702161347218</td><td>Science, Technology and Innovation Committee of Shenzhen Municipality, Shenzhen, China</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Single-Cell DNA and RNA Sequencing over A 29-Year Period of A CLL Patient</StudyNameEntrez>
	<StudyNameReportPage>Single-Cell DNA and RNA Sequencing over A 29-Year Period of A CLL Patient Demonstrating Evolution of Multiple Cell Clones</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Chronic lymphocytic leukemia (CLL) is a frequent B-cell malignancy characterized by recurrent somatic chromosome alterations and a low level of point mutations. Here we present single nucleotide polymorphism (SNP) microarray analyses of a single CLL patient over 29-years of observation and treatment, and transcriptome and whole genome sequencing at selected timepoints. We identified chromosome alterations of 13q14-, 6q- and 12q+ in early cell clones, elimination of clonal populations following therapy, and subsequent appearance of a clone containing trisomy 12 and a chromosome 10 copy neutral loss of heterogeneity (LOH) that marks a major population dominant at death. Serial single cell RNA sequencing revealed elevated mRNA expression of the FOS, JUN and KLF4 genes just before the appearance of acute disease requiring therapy. This gene expression pattern became undetectable following therapy, but reoccurred following relapse. Transcriptome evolution indicates that complex expression changes occur over time. In conclusion, CLL can evolve gradually during indolent phases, and undergo rapid changes following therapy. </p>]]>
	</Description>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Leukemia, Lymphocytic, Chronic, B-Cell"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Michael Dean, PhD</AttName>
			<Institution>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>HHSN261200800001E</AttName>
			<Institution>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>CXZZ20150330171838997</AttName>
			<Institution>Shenzhen Science and Technology Program, Shenzhen, China</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>ZDSYS20140509153457495</AttName>
			<Institution>Shenzhen Municipal Government, Shenzhen, China</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>JSGG20140702161347218</AttName>
			<Institution>Science, Technology and Innovation Committee of Shenzhen Municipality, Shenzhen, China</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-CA-MDS" longName="Disease-Specific (Cancer, MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001181.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001181.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001181.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Cancer, MDS)</ConsentName>
        <ConsentAbbrev>DS-CA-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Cancer.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
